Drug
liraglutide
Marketed as SAXENDA.
Generic name
liraglutide
Brand names
SAXENDA
First FDA approval
2014-12-23
Drug class
GLP-1 receptor agonists
Patient assistance program
NovoCare
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| NDA206321 | SAXENDA | 2014-12-23 | NOVO |
Manufacturers
NOVO
Common denial patterns
- Weight-loss exclusion (Saxenda)
- Step therapy
Specific notes
Sold as Victoza (T2D) and Saxenda (weight loss). Older GLP-1 — newer agents typically preferred.
Manufacturer patient assistance
NovoCare: https://www.novocare.com
Frequently asked questions
Why does insurance commonly deny liraglutide?
Weight-loss exclusion (Saxenda); Step therapy.
When was liraglutide FDA approved?
Earliest FDA approval on record: 2014-12-23.
What brand names are sold as liraglutide?
SAXENDA.
Is there a patient assistance program for liraglutide?
Yes — NovoCare at https://www.novocare.com.
What's specific to liraglutide?
Sold as Victoza (T2D) and Saxenda (weight loss). Older GLP-1 — newer agents typically preferred.
Related
Sources
Appeal a liraglutide denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com